NXL104 联合头孢他啶和氨曲南对产碳青霉烯酶肠杆菌科的活性。
Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae.
机构信息
Antibiotic Resistance Monitoring & Reference Laboratory, HPA Centre for Infections, London, United Kingdom.
出版信息
Antimicrob Agents Chemother. 2011 Jan;55(1):390-4. doi: 10.1128/AAC.00756-10. Epub 2010 Nov 1.
Abstract
Combinations of NXL104 with ceftazidime and aztreonam were tested against carbapenem-resistant members of the Enterobacteriaceae. Ceftazidime-NXL104 was active against strains with the OXA-48 enzyme or with combinations of impermeability and an extended-spectrum β-lactamase (ESBL) or AmpC enzyme and also against most Klebsiella spp. with the KPC enzyme, but metallo-β-lactamase producers were resistant. Aztreonam-NXL104 was active against all carbapenemase producers at 4 and 4 μg/ml, including those with metallo-β-lactamases.
摘要
NXL104 与头孢他啶和氨曲南联合用药，针对耐碳青霉烯类肠杆菌科成员进行了测试。头孢他啶-NXL104 对携带 OXA-48 酶或通透性与超广谱β-内酰胺酶（ESBL）或 AmpC 酶组合的菌株以及携带 KPC 酶的大多数克雷伯氏菌属具有活性，但对金属β-内酰胺酶产生菌具有耐药性。氨曲南-NXL104 在 4 和 4μg/ml 时对所有碳青霉烯酶产生菌均具有活性，包括携带金属β-内酰胺酶的产生菌。
相似文献
1
Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae.NXL104 联合头孢他啶和氨曲南对产碳青霉烯酶肠杆菌科的活性。
Antimicrob Agents Chemother. 2011 Jan;55(1):390-4. doi: 10.1128/AAC.00756-10. Epub 2010 Nov 1.
2
Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae.头孢洛林与 NXL104 的棋盘组合对产β-内酰胺酶肠杆菌科的活性。
J Antimicrob Chemother. 2010 Jul;65(7):1428-32. doi: 10.1093/jac/dkq161. Epub 2010 May 17.
3
In Vitro Activities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli.头孢他啶-阿维巴坦、氨曲南-阿维巴坦以及一组较老和当代抗菌药物对产碳青霉烯酶革兰氏阴性杆菌的体外活性
Antimicrob Agents Chemother. 2015 Dec;59(12):7842-6. doi: 10.1128/AAC.02019-15. Epub 2015 Sep 21.
4
Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015.2012 年至 2015 年期间，作为国际最佳耐药监测网络（INFORM）全球监测项目的一部分，分离出携带 OXA-48 酶的肠杆菌科细菌，对头孢他啶-阿维巴坦和氨曲南-阿维巴坦的活性进行评估。
Antimicrob Agents Chemother. 2018 Nov 26;62(12). doi: 10.1128/AAC.00592-18. Print 2018 Dec.
5
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .头孢他啶-阿维巴坦对产碳青霉烯酶的. 的体外和体内杀菌活性。
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
6
Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.2015-2016 年英国分离的产 ESBL 肠杆菌科细菌和铜绿假单胞菌对头孢他啶/阿维巴坦的活性。
J Antimicrob Chemother. 2018 Mar 1;73(3):648-657. doi: 10.1093/jac/dkx438.
7
Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.在法国一项前瞻性区域间调查中收集的碳青霉烯不敏感肠杆菌分离株的分子特征以及对新型头孢他啶-阿维巴坦和氨曲南-阿维巴坦联合制剂的敏感性
Antimicrob Agents Chemother. 2015 Oct 19;60(1):215-21. doi: 10.1128/AAC.01559-15. Print 2016 Jan.
8
NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases.NXL104联合用药对产CTX-M超广谱β-内酰胺酶和碳青霉烯酶的肠杆菌科细菌的作用
J Antimicrob Chemother. 2008 Nov;62(5):1053-6. doi: 10.1093/jac/dkn320. Epub 2008 Aug 9.
9
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?头孢他啶-阿维巴坦和氨曲南能否克服肠杆菌科细菌中金属β-内酰胺酶介导的β-内酰胺耐药性？
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02243-16. Print 2017 Apr.
10
In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases.β-内酰胺酶抑制剂NXL104对KPC-2碳青霉烯酶及表达KPC碳青霉烯酶的肠杆菌科细菌的体外活性
J Antimicrob Chemother. 2009 Aug;64(2):326-9. doi: 10.1093/jac/dkp197. Epub 2009 Jun 2.
引用本文的文献
1
Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients.群体药代动力学/药效学建模以优化成人患者的氨曲南-阿维巴坦给药方案。
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0195024. doi: 10.1128/aac.01950-24. Epub 2025 Jun 18.
2
[In vitro activity of ceftazidime- avibactam and ceftolozane- tazobactam against clinical isolates of enterobacteriaceae and : results from a trauma center and burn unit in tunisia].[头孢他啶-阿维巴坦和头孢洛扎-他唑巴坦对突尼斯一家创伤中心和烧伤科肠杆菌科临床分离株的体外活性：结果]
Ann Burns Fire Disasters. 2025 Mar 31;38(1):31-37. eCollection 2025 Mar.
3
Antimicrobial Resistance - The 'Real' Pandemic We Are Unaware Of, Yet Nearby.抗微生物药物耐药性——我们尚未意识到却近在咫尺的“真正”大流行。
J Korean Med Sci. 2025 May 19;40(19):e161. doi: 10.3346/jkms.2025.40.e161.
4
Aztreonam-avibactam Demonstrates Potent Activity Against Carbapenem-resistant Enterobacterales Collected From US Medical Centers Over a 6-year Period (2017-2022).氨曲南-阿维巴坦对2017年至2022年这6年间从美国医疗中心收集的耐碳青霉烯类肠杆菌科细菌显示出强大活性。
Open Forum Infect Dis. 2025 Apr 25;12(5):ofaf250. doi: 10.1093/ofid/ofaf250. eCollection 2025 May.
5
The Triple Combination of Meropenem, Avibactam, and a Metallo-β-Lactamase Inhibitor Optimizes Antibacterial Coverage Against Different β-Lactamase Producers.美罗培南、阿维巴坦和一种金属β-内酰胺酶抑制剂的三联组合优化了针对不同β-内酰胺酶产生菌的抗菌覆盖范围。
Engineering (Beijing). 2024 Jul;38:124-132. doi: 10.1016/j.eng.2024.02.010.
6
Tackling the outer membrane: facilitating compound entry into Gram-negative bacterial pathogens.攻克外膜：促进化合物进入革兰氏阴性菌病原体。
NPJ Antimicrob Resist. 2023 Dec 20;1(1):17. doi: 10.1038/s44259-023-00016-1.
7
Impact of the inoculum size on the activity of the aztreonam-avibactam combination in a murine model of peritonitis due to expressing CTX-M-15 and NDM-1.接种量对在因表达CTX-M-15和NDM-1而引发的腹膜炎小鼠模型中氨曲南-阿维巴坦联合用药活性的影响。
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0128822. doi: 10.1128/aac.01288-22. Epub 2024 Dec 19.
8
Novel plasmid-mediated CMY variant (CMY-192) conferring ceftazidime-avibactam resistance in multidrug-resistant .新型质粒介导的CMY变体（CMY-192）赋予多重耐药菌对头孢他啶-阿维巴坦的耐药性 。
Antimicrob Agents Chemother. 2024 Dec 5;68(12):e0090624. doi: 10.1128/aac.00906-24. Epub 2024 Oct 29.
9
Gas Chromatography-Ion Mobility Spectrometry Reveals Acetoin as a Biomarker for Carbapenemase-Producing Klebsiella pneumoniae.气相色谱-离子淌度谱法揭示乙酰-3-羟丁酮是产碳青霉烯酶肺炎克雷伯菌的生物标志物。
Med Sci Monit. 2024 Jul 31;30:e944507. doi: 10.12659/MSM.944507.
10
Role of β-Lactamase Inhibitors as Potentiators in Antimicrobial Chemotherapy Targeting Gram-Negative Bacteria.β-内酰胺酶抑制剂作为增效剂在针对革兰氏阴性菌的抗菌化疗中的作用。
Antibiotics (Basel). 2024 Mar 15;13(3):260. doi: 10.3390/antibiotics13030260.
本文引用的文献
1
Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study.印度、巴基斯坦和英国出现新的抗生素耐药机制：一项分子、生物学和流行病学研究。
Lancet Infect Dis. 2010 Sep;10(9):597-602. doi: 10.1016/S1473-3099(10)70143-2. Epub 2010 Aug 10.
2
Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae.头孢洛林与 NXL104 的棋盘组合对产β-内酰胺酶肠杆菌科的活性。
J Antimicrob Chemother. 2010 Jul;65(7):1428-32. doi: 10.1093/jac/dkq161. Epub 2010 May 17.
3
Spread of OXA-48-encoding plasmid in Turkey and beyond.OXA-48 编码质粒在土耳其及其他地区的传播。
Antimicrob Agents Chemother. 2010 Mar;54(3):1369-73. doi: 10.1128/AAC.01312-09. Epub 2010 Jan 19.
4
Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues.革兰氏阴性细菌病原体中获得性碳青霉烯酶：检测和监测问题。
Clin Microbiol Infect. 2010 Feb;16(2):112-22. doi: 10.1111/j.1469-0691.2009.03116.x.
5
Three decades of beta-lactamase inhibitors.三十年的β-内酰胺酶抑制剂。
Clin Microbiol Rev. 2010 Jan;23(1):160-201. doi: 10.1128/CMR.00037-09.
6
Colonization of residents and staff of a long-term-care facility and adjacent acute-care hospital geriatric unit by multiresistant bacteria.长期护理机构居民和工作人员以及毗邻急性护理医院老年病房的多重耐药菌定植。
Clin Microbiol Infect. 2010 Jul;16(7):934-44. doi: 10.1111/j.1469-0691.2009.03024.x. Epub 2009 Aug 17.
7
In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases.NXL104与β-内酰胺类药物联合对产KPC碳青霉烯酶的肺炎克雷伯菌分离株的体外活性。
Antimicrob Agents Chemother. 2009 Aug;53(8):3599-601. doi: 10.1128/AAC.00641-09. Epub 2009 Jun 15.
8
Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258.美国产KPC肺炎克雷伯菌分离株的分子流行病学：多位点序列类型258的克隆扩增
Antimicrob Agents Chemother. 2009 Aug;53(8):3365-70. doi: 10.1128/AAC.00126-09. Epub 2009 Jun 8.
9
The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria.产肺炎克雷伯菌碳青霉烯酶细菌的真正威胁。
Lancet Infect Dis. 2009 Apr;9(4):228-36. doi: 10.1016/S1473-3099(09)70054-4.
10
Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK.破坏英国产耐厄他培南克雷伯菌和肠杆菌临床分离株中孔蛋白表达的分子机制。
J Antimicrob Chemother. 2009 Apr;63(4):659-67. doi: 10.1093/jac/dkp029. Epub 2009 Feb 20.
Zotero 插件